Libro blanco de las ACES Pediátricas 2024

Hematología y Oncología Pediátricas. Anexos ❚ 319 European Training Programme in Paediatric Haematology and Oncology    _________________________________________________________________________________________ SIOP Europe – March 2020 Module 3: Diagnosis, Treatment and Follow-Up LEUKEMIA (ALL, AML)   Constitutional and genetic conditions predisposing to leukemia    Genetic classification    Management of the treatment‐related complications, including tumor lysis, coagulopathy,  thrombosis, infections, septic shock   Treatment according to different types of leukemia    Indications for bone marrow transplant    Current role of radiotherapy and associated complications    Cytogenetic and molecular aspects affecting prognosis and treatment in infants and  children    Clinical, laboratory and molecular response to treatment for prognosis and treatment plan   Management of testicular, CNS and bone marrow relapse   Late effects and long‐term follow‐up  MDS and JMML   Management of myelodysplastic syndrome and rarer forms of childhood leukemia (such as  chronic myeloid leukemia and juvenile myelomonocytic leukemia)   Differential diagnoses of pancytopenia   Management options of low‐grad MDS; observation, immunotherapy, HSCT   Management options of MDS with excess of blasts; limited effect of chemotherapy, HSCT   Diagnostics of JMML by clinical, haematological and genetic factors   Therapy depending on genetics varying from observation to HSCT   CML: knowledge of the initial therapy, cytoreductive therapy, and long‐term therapy with  tyrosine kinase inhibitors   Late effects and long‐term follow‐up  HODGKIN’S DISEASE   Histological subtypes and influence on prognosis   Diagnostic procedures   Role of FDG‐PET at diagnosis and in assessment of response and treatment intensity   Staging, stratification and therapy of patients according to international protocols   Potential late effects related to chemotherapy and radiotherapy: increased risk of second  cancers mainly in patients receiving radiotherapy, cardiac and lung dysfunction, damage of  reproductive function